绥美凯的治疗效果

Inbec is indicated for the treatment of adults and adolescents over 12 years of age (who weigh at least 40kg) infected with human immunodeficiency virus (HIV). On January 22, 2018, GlaxoSmithKline (GSK) announced that the single-tablet compound preparation Triumeq (Dolutegravir Tablets) for the treatment of HIV was officially launched in mainland China. Triumeq Inbec is the only three-in-one compound drug containing dolutegravir. It takes one tablet once a day and has the characteristics of high efficiency, good tolerance, high resistance barrier and few drug interactions.

Specifications of Suimeikan Inbec: Each tablet contains dolutegravir (DTG) 50mg, abacavir (ABC) 600mg and lamivudine (3TC) 300mg. Suimeikan Inbec should be taken orally under the guidance of a physician experienced in treating HIV infection. Suimeike Inbec is not affected by food. Dosage: One tablet, once daily. It is not recommended for those whose creatinine clearance is less than 50ml/min.

Due to patent protection restrictions, many drugs are prohibited from being copied in most countries around the world. However, due to the protection of India's special patent laws, Indian Emcure Pharmaceuticals can produce drugs that are almost as effective as the original drugs and have high cost performance.

The therapeutic effect of Trimax of Indian Emcure Pharmaceuticals: Trimax is a drug containing three active ingredients. Existing research shows that one year (48 weeks) after treatment with Trimax in HIV-infected patients, 93% of the infected people's viral load became negative.

Inbec has remarkable effects and is relatively safe. Common side effects of Suimeikai Inbec include nausea/insomnia/dizziness/headache, etc. Patients with abacavir hypersensitivity often experience symptoms such as nausea, vomiting, diarrhea, fever, drowsiness, rash and other symptoms when using Trimax Inbec. If patients experience these symptoms, they should be carefully evaluated for the presence of such a hypersensitivity reaction.

Recommended related hot articles: /newsDetail/87207.html